P21 vs SHLP2
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
P21
P21 is a synthetic peptide derived from Cerebrolysin, specifically designed to mimic the neurotrophic effects of the parent compound. It promotes neurogenesis and has shown cognitive-enhancing properties in research.
Full details →SHLP2
SHLP2 (Small Humanin-Like Peptide 2) is a mitochondrial-derived peptide similar to humanin. It has shown insulin-sensitizing and cytoprotective effects in research, with potential metabolic benefits.
Full details →Side-by-Side Comparison
| Aspect | P21 | SHLP2 |
|---|---|---|
| Mechanism | Inhibits glycogen synthase kinase-3β (GSK-3β) and activates CREB signaling pathway. This promotes BDNF expression, neurogenesis in the hippocampus, and synaptic plasticity. | Enhances insulin sensitivity and glucose uptake. Provides cytoprotective effects similar to humanin. May act through similar but distinct receptor pathways. |
| Typical Dosage | Research protocols typically use 1-5mg administered intranasally or subcutaneously. Often used in cycles of 2-4 weeks. | Research compound with doses in the microgram to low milligram range studied in animal models. Human dosing not established. |
| Administration | Can be administered intranasally for direct CNS access or subcutaneously. Best used cyclically rather than continuously. | Subcutaneous or intraperitoneal injection in research settings. Various SHLP analogs (1-6) have different properties. |
| Side Effects | Limited data. Reported effects include mild headache, temporary brain fog during initial use, and fatigue. | Limited data. Animal studies suggest good tolerability. May affect glucose metabolism. |
| Best For |